The President’s proposed budget for Fiscal Year 2026 would eliminate the CDC’s Division of Cancer Prevention and Control (DCPC). This division supports the only federally funded education and screenin...

John Moroney, MD, and Katherine Kurnit, MD, MPH, emphasize the importance of timing in gynecologic cancer clinical trials.

Five gynecologic cancers, five different stories, and five different ways to recognize risk, spot warning signs, pursue screening, and take action.

New Study Explores Sexual Health After Chemotherapy for Breast and Gynecologic Cancer - MASCC / cancer, Katherine Conroy, Kristen M. Carpenter, Lora L. Black,

Interviews with patients revealed that sexual health discussions are a vital part of overall cancer care for women with gynecologic cancers.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss the most interesting recent trends in clinical trials in gynecologic oncology.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss their approaches to supporting patients with gynecologic malignancies during clinical trials.

Studies have shown that patient education and communication positively affect patient health outcomes, including emotional and physical health.

John Moroney, MD, and Katherine Kurnit, MD, MPH, discuss which future advances being examined in clinical trials in gynecologic oncology are catching their eyes.

Purpose Sexual inactivity has been shown to be a predictor of future sexual problems and related distress in female cancer survivors; however, very little is known about the sexual lives of women in active treatment. The aims of present study are to estimate rates of sexual activity during adjuvant chemotherapy and their relationship to sexual outcomes 12 months after therapy initiation. Methods Self-report questionnaires were completed by gynecologic and breast cancer patients (n = 58) prior to their first chemotherapy infusion, at three timepoints during treatment, and at follow-up 1 year later. Questionnaires assessed sexual activity, sexual desire, sexual arousal, sexual satisfaction, depressive symptoms, and treatment toxicities. Results Engagement in sexual activity during chemotherapy was significantly associated with reports of experiencing sexual desire (B = 1.94, p = .03), arousal (B = 3.31, p = .01), and higher satisfaction ratings (β = .33, p = .02) 12 months after the initiation of chemotherapy. Conclusions The results indicate that remaining sexually active during treatment is associated with better sexual function and higher sexual satisfaction in the year following chemotherapy initiation.

Dana M. Chase, MD, and Angeles Alvarez Secord, MD, MHSc, discuss mocertatug rezetecan in gynecologic malignancies.